{'fraction_non_alphanumeric': 0.0416227900016627, 'fraction_numerical': 0.0287646178573408, 'mean_word_length': 5.002661343978709, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effect of lncRNA HULC knockdown on rat secreting pituitary adenoma GH3 cells

Pituitary adenoma is one of the most common tumors in the neuroendocrine system. This study investigated the effects of long non-coding RNAs (lncRNAs) highly up-regulated in liver cancer (HULC) on rat secreting pituitary adenoma GH3 cell viability, migration, invasion, apoptosis, and hormone secretion, as well as the underlying potential mechanisms. Cell transfection and qRT-PCR were used to change and measure the expression levels of HULC, miR-130b, and FOXM1. Cell viability, migration, invasion, and apoptosis were assessed using trypan blue staining assay, MTT assay, two-chamber transwell assay, Guava Nexin assay, and western blotting. The concentrations of prolactin (PRL) and growth hormone (GH) in culture supernatant of GH3 cells were assessed using ELISA. The targeting relationship between miR-130b and FOXM1 was verified using dual luciferase activity. Finally, the expression levels of key factors involved in PI3K/AKT/mTOR and JAK1/STAT3 pathways were evaluated using western blotting. We found that HULC was highly expressed in GH3 cells. Overexpression of HULC promoted GH3 cell viability, migration, invasion, PRL and GH secretion, as well as activated PI3K/AKT/mTOR and JAK1/STAT3 pathways. Knockdown of HULC had opposite effects and induced cell apoptosis. HULC negatively regulated the expression of miR-130b, and miR-130b participated in the effects of HULC on GH3 cells. FOXM1 was a target gene of miR-130b, which was involved in the regulation of GH3 cell viability, migration, invasion, and apoptosis, as well as PI3K/AKT/mTOR and JAK1/STAT3 pathways. In conclusion, HULC tumor-promoting roles in secreting pituitary adenoma might be via down-regulating miR-130b, up-regulating FOXM1, and activating PI3K/AKT/mTOR and JAK1/STAT3 pathways.


Introduction
Pituitary adenoma, characterized by uncontrolled proliferation of pituitary gland cells, is one of the most common tumors in the neuroendocrine system (1,2). Pituitary adenomas can be divided into secreting and non-secreting pituitary adenomas (3). The clinical symptoms of secreting pituitary adenoma are dysfunction of the endocrine system, such as decreased libido, infertility, galactorrhea, and neurologic compression (like headaches and visual changes) (4). With the development of diagnostic and therapeutic methods, the 5-year survival rate of patients with secreting pituitary adenoma has increased in recent years (5,6). However, considering that the pathogenesis of this tumor is very complex (7,8), a clearer understanding of the process will be helpful for defining more effective diagnostic and therapeutic strategies.
Long non-coding RNAs (lncRNAs) have been proved to exert critical regulatory roles in many biological processes, including cell proliferation, differentiation, and apoptosis (9). Aberrant expressions of lncRNAs have been linked to many human diseases, including secreting pituitary adenomas (10,11). As one kind of lncRNAs, highly up-regulated in liver cancer (HULC) is a key regulatory molecule that participates in the development and progression of hepatocellular carcinoma (12). Some studies in recent years demonstrated that HULC was also involved in the occurrence and development of other human cancers, such as osteosarcoma (13), epithelial ovarian carcinoma (14), bladder cancer (15), glioma (16), breast cancer (17), and chronic myeloid leukemia (18). However, there is no information available about the effects of HULC on pituitary adenoma, including secreting pituitary adenoma.
Similar to lncRNAs, microRNAs (miRNAs) also have important functions in the regulation of multiple cellular biological processes (19). Furthermore, lncRNAs can exert oncogenic or tumor suppressive roles by regulating the expressions of miRNAs in cells (20). miRNA-130b (miR-130b) has been shown to participate in cell proliferation and metastasis in many cancer cell lines (21). Leone et al. (22) reported that miR-130b was downregulated in secreting pituitary adenoma.
Forkhead box protein M1 (FOXM1) is a typical cell proliferation-associated transcription factor, which stimulates cell proliferation by promoting S-phase and M-phase entries in cell cycle transition (23). Several reports provide evidence that the expression of FOXM1 is up-regulated in a variety of cancer cells (24). Many miRNAs can modulate the expression of FOXM1 in cancer cells (25,26). However, the role of FOXM1 in the regulation of secreting pituitary adenoma cell proliferation remains unclear.
Hence, in this research, we aimed to explore the effects of HULC on rat secreting pituitary adenoma GH3 cell line viability, migration, invasion, apoptosis, and hormone secretion, as well as miR-130b expression. The regulatory effect of miR-130b on FOXM1 expression in GH3 cells and regulatory roles of FOXM1 in GH3 cell viability, migration, invasion, and apoptosis were also investigated. Our findings will be helpful for further understanding the pathogenesis of secreting pituitary adenoma and provide potential diagnostic and therapeutic targets for secreting pituitary adenoma.

Isolation of rat pituitary primary cells
Three male Wistar rats (4 weeks, 124±12 g) were obtained from Shandong Laboratory Animal Center (China). Rats were acclimated in a temperature-controlled and specific pathogen-free environment for 4 days. Then, rats were sacrificed and the pituitary tissues were collected on ice. Subsequently, pituitary tissues were cut and trypsinized. The pituitary primary cells were collected by centrifugation (800 g, room temperature, 5 min).
For the MTT assay, after relevant transfection, GH3 cells were seeded into a 96-well plate (Thermo Fisher Scientific) with 1 Â 10 4 cells per well and cultured at 37°C for 24 h. Then, 20 mL MTT solution (2.5 mg/mL in PBS) was added into the medium of each well and the plate was incubated at 37°C for 4 h. Subsequently, the MTT mixture was removed and 150 mL dimethyl sulfoxide (DMSO) was added to dissolve formazan. After that, the plate was agitated on a shaker for 15 min. The absorbance of each well at 570 nm was recorded using a microplate reader (Bio-Tek Instrument, USA).

Cell migration and invasion assay
Cell migration was determined using a modified twochamber transwell assay (Corning Incorporated, USA). Briefly, after relevant transfection, 1 Â 10 3 GH3 cells were suspended in 200 mL serum free-DMEM and added into the upper chamber. Complete DMEM (600 mL) was added into the lower chamber. After incubation at 37°C for 48 h, cells were immediately fixed with 4% paraformaldehyde solution (Beyotime Biotechnology, China). Then, nonmigrated cells in the upper chamber were removed carefully using a cotton swab and migrated cells in the lower chamber were counted under a microscope (Nikon, Japan). Cell migration (%) was calculated by average number of migrated cells in transfection group / average number of migrated cells in control group Â 100%.
Cell invasion was evaluated similarly with cell migration, except that the transwell membrane was pre-incubated using Matrigel (BD Biosciences, USA). Cell invasion (%) was calculated by average number of invaded cells in transfection group / average number of invaded cells in control group Â 100%.

Cell apoptosis assay
Guava Nexin assay (Millipore Billerica, USA) was used to detect the apoptosis of GH3 cells. Briefly, after relevant transfection, GH3 cells were seeded into a 6-well plate with 1 Â 10 5 cells per well and cultured at 37°C for 24 h. Then, cells were collected, washed with PBS, stained using the kit solution, and subjected to flow cytometry analysis (Guava easyCyte 8HT, Millipore Billerica, USA). Data were analyzed using FCS Express software (De Novo software, USA).

Enzyme linked immunosorbent assay (ELISA)
ELISA was conducted to measure the concentrations of prolactin (PRL) and growth hormone (GH) in culture supernatant of GH3 cells. Briefly, after relevant transfection, GH3 cells were seeded into a 6-well plate with 1 Â 10 5 cells per well and cultured at 37°C for 24 h. Then, the cell supernatant of each group was collected and concentrations of PRL and GH were measured using rat PRL ELISA kit and rat GH ELISA kit (Invitrogen), respectively.

Dual luciferase activity assay
The 3 0 untranslated region (UTR, 2257-3049 bp) fragment of FOXM1, containing the predicted miR-130b binding site, was amplified by PCR and constructed in pmirGLO vector (Promega, USA) to form FOXM1-wild type (FOXM1wt). To mutate the predicted miR-130b binding site, the predicted binding site was replaced, amplified, and constructed in pmirGLO vector to form FOXM1-mutated type (FOXM1-mt). The sequence of FOXM1-wt was 5 0 -CAAAG GCAAUGGUGAAAAGAGAU-3 0 and the sequence of FOX M1-mt was 5 0 -CAAAGGCAAUGGUGACAGUUAAU-3 0 . Then, miR-130b mimic and reporter vectors were transfected into HEK293 cells simultaneously. The relative luciferase activity was detected using dual-luciferase reporter assay system (Promega).

Statistical analysis
All experiments were conducted at least three times. Results of multiple experiments are reported as means± SD. Graphpad 6.0 software (Graphpad, USA) was used for statistical analysis. P values were calculated using one-way analysis of variance (ANOVA). Statistically significant differences were set at Po0.05.

HULC was highly expressed in GH3 cells
Firstly, we detected the expression level of HULC in rat pituitary primary cells and rat secreting pituitary adenoma GH3 cells. The results in Figure 1 show that HULC was highly expressed in GH3 cells, compared to rat pituitary primary cells (Po0.01). This finding suggested that HULC might exert oncogenic roles in secreting pituitary adenoma. Figure 2A shows that the expression level of HULC was significantly decreased after sh-HULC transfection (Po0.01) and increased after pc-HULC transfection (Po0.01). Figure 2B-E shows that knockdown of HULC remarkably suppressed the viability, migration, and invasion of GH3 cells (Po0.05 or Po0.01). On the contrary, overexpression of HULC had opposite effects, which notably enhanced the viability, migration, and invasion of GH3 cells (Po0.05 or Po0.01). Figure 2F shows that TGF-b treatment promoted GH3 cell migration and invasion via reducing the expression level of E-cadherin and enhancing the expression levels of N-cadherin, vimentin, and Snail. Compared to the TGF-b single treatment group, the expression level of E-cadherin was increased, and the expression levels of N-cadherin, vimentin, and Snail were decreased in TGF-b treatment+sh-HULC transfection group. pc-HULC transfection had opposite effects.

HULC exerted oncogenic roles in GH3 cells
Moreover, the results of Figure 2G show that HULC knockdown markedly induced GH3 cell apoptosis (Po0.01). Western blotting showed that the expression levels of cleaved-PARP, cleaved-caspase 3, and cleaved-caspase 9 in GH3 cells were all increased after HULC knockdown ( Figure 2H). Furthermore, Figure 2I and J show that HULC knockdown notably reduced the concentrations of PRL and GH in culture supernatant of GH3 cells (Po0.05). On the contrary, overexpression of HULC dramatically enhanced the concentrations of PRL and GH in culture supernatant of GH3 cells (Po0.05). Taken together, these results suggested that HULC exerted oncogenic roles in GH3 cells. Knockdown of HULC inhibited GH3 cell viability, migration, invasion, and hormone secretion, but promoted cell apoptosis.

HULC negatively regulated the expression of miR-130b in GH3 cells
The expression level of miR-130b in GH3 cells after HULC knockdown or overexpression was measured using qRT-PCR. As presented in Figure 3, HULC knockdown enhanced the expression level of miR-130b (Po0.01) and overexpression of HULC significantly reduced the expression level of miR-130b in GH3 cells (Po0.05). This finding indicated that HULC negatively regulated the expression of miR-130b in GH3 cells and implied that miR-130b might be involved in the effects of HULC on GH3 cells.

FOXM1 was target gene of miR-130b in GH3 cells
The mRNA and protein expression levels of FOXM1 in GH3 cells after miR-130b mimic or miR-130b inhibitor transfection were detected in this research. As displayed in Figure 5A, the mRNA and protein expression levels of FOXM1 in GH3 cells were reduced after miR-130b mimic transfection (Po0.05 in mRNA level) and enhanced after miR-130b inhibitor transfection (Po0.01 in mRNA level). Figure 5B shows that the relative luciferase activity was notably decreased after co-transfection with miR-130b mimic and FOXM1-wt (Po0.05). The potential binding sequence between miR-130b and 3 0 UTR of FOXM1 is shown in Figure 5C. These findings indicated that miR-130b negatively regulated the expression of FOXM1 and FOXM1 was a target gene of miR-130b in GH3 cells.
tumor suppressors, and exert critical regulatory roles in the carcinogenesis of multiple cancers, including pituitary adenoma (19). In this study, we revealed that HULC had a higher expression level in secreting pituitary adenoma GH3 cells, compared to rat pituitary primary cells. Overexpression of HULC significantly promoted the viability, migration, invasion, and hormone secretion of GH3 cells, as well as down-regulated the expression of miR-130b. Knockdown of HULC had opposite effects and induced GH3 cell apoptosis. Furthermore, we also found that FOXM1 was a target gene of miR-130b in GH3 cells and participated in the regulation of GH3 cell viability, migration, invasion, and apoptosis, as well as PI3K/AKT/mTOR and JAK1/STAT3 signaling pathways.
lncRNAs do not encode proteins, but play important roles in the regulation of gene expression in cells (9,30). Numerous studies have proved the oncogenic roles of HULC in cancer cells by their contribution on cancer cell proliferation and metastasis (13,15). For example, Chen et al. (14) reported that overexpression of HULC promoted proliferation, migration, and invasion of epithelial ovarian carcinoma cells. Matouk et al. (31) indicated that HULC was related to metastasis of colorectal carcinomas. Our results were consistent with previous studies. Figure 6. After pc-FOXM1 or sh-FOXM1 transfection, A, the mRNA and protein levels of FOXM1, B-E, the viability, migration, invasion, and apoptosis of GH3 cells, and F, the expression levels of PARP, cleaved-PARP, pro-caspase 3, cleaved-caspase 3, pro-caspase 9, and cleaved-caspase 9 in GH3 cells were assessed using qRT-PCR, western blotting, trypan blue staining assay, two-chamber transwell assay, and Guava Nexin assay. FOXM1: Forkhead box protein M1; NC: negative control; PARP: poly ADP-ribose polymerase. Data are reported as means ± SD. *Po0.05; **Po0.01 (ANOVA).
Abnormal hormone secretion is one of the major complications of secreting pituitary adenomas (32). As a rat secreting pituitary adenoma cell line, GH3 can also secret PRL and GH (33). Therefore, we also assessed the PRL and GH levels in culture supernatant of GH3 cells after HULC overexpression or knockdown. Taken together, Figure 7. Overexpression of FOXM1 activated PI3K/AKT/mTOR and JAK1/STAT3 pathways in GH3 cells. (A and B) The expression levels of p-PI3K, t-PI3K, p-AKT, t-AKT, p-mTOR, t-mTOR, p-JAK1, t-JAK1, p-STAT3, and t-STAT3 in GH3 cells after pc-HULC or sh-HULC transfection were evaluated using western blotting. (C and D) The expression levels of the same proteins in GH3 cells after pc-FOXM1 or sh-FOXM1 transfection were evaluated using western blotting. HULC: Highly up-regulated in liver cancer; FOXM1: forkhead box protein M1; NC: negative control; PI3K: phosphatidylinositol 3-kinase; AKT: protein kinase 3; mTOR: mammalian target of rapamycin; JAK1: janus kinase 1; STAT3: signal transducing activator of transcription 3. Data are reported as means ± SD.*Po0.05; **Po0.01 (ANOVA). our results revealed the critical roles of HULC in regulating rat secreting pituitary adenoma cell proliferation, metastasis, and hormone secretion.
One of the most important findings in this research was that HULC negatively regulated the expression of miR-130b in GH3 cells. Reports have proved that miRNAs are involved in the regulation of intracellular gene expression at the post-transcriptional level (19,34). miR-130b has been demonstrated to be down-regulated in pituitary adenomas cells, including secreting pituitary adenoma (22). The findings of the present study suggested that HULC exerted oncogenic roles in rat secreting pituitary adenoma GH3 cells at least in part by down-regulating miR-130b.
As a typical cell proliferation-associated transcription factor, FOXM1 plays important roles in regulating cell proliferation (35). Moreover, FOXM1 has a high expression level in many human cancer cells (24,36). In this study, we revealed that FOXM1 was a target gene of miR-130b in GH3 cells. The findings indicated that miR-130b participated in the effects of HULC on GH3 cells, which might be through regulating FOXM1.
PI3K/AKT/mTOR and JAK1/STAT3 signaling pathways play critical roles in the regulation of multiple cell functions, such as cell proliferation, cell invasion, and cell apoptosis (37,38). Tian et al. (39) proved that miR-361-5p inhibited chemo-resistance of gastric cancer cells by targeting FOXM1 and PI3K/AKT/mTOR signaling pathway. Buslei et al. (40) reported that the activation of JAK1/ STAT3 signaling pathway contributed to the development of pituitary adenoma. Thus, in this research, we also analyzed the effects of HULC and FOXM1 on the activation of PI3K/AKT/mTOR and JAK1/STAT3 pathways in GH3 cells. The results suggested that HULC exerted oncogenic roles in GH3 cells, which might be via down-regulating miR-130b, up-regulating FOXM1, and then activating PI3K/ AKT/mTOR and JAK1/STAT3 pathways.
In summary, our research verified the oncogenic roles of HULC in rat secreting pituitary adenoma GH3 cells. This study contributes to the further understanding of the pathogenesis of secreting pituitary adenomas and is helpful for defining potential diagnostic and therapeutic targets.